

eTable 5. Michelson Withdrawal Symptom Scale Scores, by Random Assignment		
Cycle of Participation	Active	Placebo
Cycle 1	72.9 (29.3)	68.1 (25.4)
Cycle 2	73.4 (29.9)	75.2 (33.1)
Cycle 3	70.3 (27.9)	71.7 (39.0)
Cycle 4	62.3 (25.1)	65.4 (25.3)
Cycle 5	63.9 (19.9)	62.1 (24.0)
Cycle 6	67.5 (22.1)	76.2 (34.1)
Main Group Effect	F(1,209)=0.55, p=0.46	
Time slope	F(6,631)=6.41, p<0.001	
Group by Time Effect	F(6,640)=0.65, p=0.69	
Estimated Mean difference from baseline to end point between active vs. placebo (95% CI)	1.02 (0.83 – 1.26)	
<p>The 16-item Michelson Withdrawal was collected prospectively during the 3 days after pills were discontinued. Scores were summed across the 3 days.</p>		

eTable 6. Adverse Events by Random Assignment				
	Active (n=125)	Placebo (n=127)	Difference	Significance
Nausea	35	15	20	<0.001
Diarrhea	22	14	8	0.18
Headache	14	19	5	0.38
Insomnia	22	9	13	0.02
Fatigue	15	14	1	0.85
Mouth dryness	13	5	8	0.06
Difficulty concentrating	8	9	1	0.81
Anxiety, agitation	10	6	4	0.32
Diaphoresis	6	10	4	0.32
Dizziness/lightheadedness	9	6	3	0.44

